News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Pancreas → cancer profile · × Clear filters
A serpin–myeloid axis in pancreatic cancer heterogeneity and immune evasion
SERPINE1 and SERPINB2 drive the formation of fibrin-rich niches in pancreatic ductal adenocarcinoma that locally reprogram macrophages toward an immunosuppressive phenotype and exclude cytotoxic T cells, establishing spatially organized immune evasion. The study, published in Nature, reveals a mechanistic serpin–myeloid axis that explains intra-tumoral heterogeneity in immune infiltration across d…
Resected pancreatic cancer: the advantage of mFOLFIRINOX over gemcitabine was seen only in KRAS-mutated tumours — molecular analysis of PRODIGE-24
A molecular analysis of the randomised PRODIGE-24/CCTG PA6 trial sequenced 317 of 350 resected pancreatic adenocarcinomas (168 patients treated with mFOLFIRINOX, 149 with gemcitabine). The advantage of mFOLFIRINOX over gemcitabine in disease-free survival was confined to KRAS-mutated tumours (sHR 0.60; 95% CI 0.45-0.79; p<0.001), with no benefit demonstrated in KRAS wild-type tumours. In the mFOLF…
Deep-learning model reading histology slides identifies which pancreatic cancer patients benefit from a given adjuvant chemotherapy regimen
Deep learning applied to routine histology slides from resected pancreatic cancer produced a biomarker (PANCprAId) predicting which patients derive greater benefit from gemcitabine versus mFOLFIRINOX. The model was developed in 231 patients who underwent pancreatectomy and received adjuvant chemotherapy, then examined in the randomised PRODIGE-24/CCTG PA6 trial (n=313), where the identified subgro…
Six-year follow-up of a personalised mRNA vaccine in pancreatic cancer: 7 of 8 immune responders alive (phase 1, 16 patients)
In a phase 1 trial of autogene cevumeran — a personalised mRNA vaccine given after resection of pancreatic cancer — 8 of 16 patients mounted a tumour-specific immune response. After 4-6 years of follow-up, 7 of those 8 were alive, compared with 2 of 8 non-responders (median survival 3.4 years). The data were presented at the 2026 AACR Annual Meeting. The study was small and non-randomised, so the …
Alcohol-attributable cancer deaths in the USA doubled between 1990 and 2023
Cancer deaths attributable to alcohol in the USA rose from 11,361 in 1990 to 23,126 in 2023 — a doubling over 33 years. The figures come from a secondary analysis of Global Burden of Disease data, so they are attributable-fraction estimates rather than counted deaths: they describe the scale of the problem in a population, not the risk faced by any one person. Increases spanned liver, breast, colo…
l -Glutamine’s potential to enhance chemotherapy efficacy in advanced pancreatic cancer
The study had a single arm and its results were compared with historical benchmarks rather than a randomised control group, so it does not establish that L-glutamine prolongs survival. Within that design, adding oral L-glutamine to first-line gemcitabine plus nab-paclitaxel in untreated advanced pancreatic cancer was safe and was associated with better survival outcomes and tumour responses than t…
FDA approves daraxonrasib, a first-in-class RAS inhibitor, in previously treated metastatic pancreatic cancer
On 26 August 2026 the FDA approved daraxonrasib (Rasonque), a first-in-class inhibitor of RAS proteins, for adults with metastatic pancreatic ductal adenocarcinoma after at least one prior systemic therapy or who are not candidates for multiagent chemotherapy. In the randomised phase 3 RASolute 302 trial (500 patients, compared with physician's choice chemotherapy) median overall survival was 13.2…
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
Adding metastasis-directed therapy (MDT — radiotherapy in 98% of lesions) to standard-of-care systemic therapy improved progression-free survival in oligometastatic disease: HR 0.54 (95% CI 0.41-0.72; P<.001) in the randomized phase 2 EXTEND trial (334 patients in the per-protocol analysis, median follow-up 53 months). The benefit persisted after excluding the two prostate baskets (HR 0.60; 95% CI…
Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848
Adding chemoradiotherapy to adjuvant chemotherapy after curative-intent resection of pancreatic head adenocarcinoma did NOT improve overall survival — the primary endpoint of the phase 3 NRG Oncology/RTOG 0848 trial (n=354) was not met (HR 0.96; 90% CI 0.79-1.18; two-sided P=.77). Median overall survival was 2.6 years with chemotherapy alone versus 2.3 years with added chemoradiotherapy, and 5-yea…
Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer
Tang et al. constructed a cell-type-resolved prognostic atlas for pancreatic cancer by integrating single-nucleus RNA transcriptomes with long-term survival data from 152 patients. The study moves beyond bulk-level gene-expression analyses to pinpoint which specific cell populations within the tumor microenvironment drive differences in patient outcomes. This framework links intra-tumoral heteroge…